1 A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

2 A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

3 Is monotherapy for febrile neutropenia still a viable alternative?

4 Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study

5 Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole

6 Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison

7 What happens after complete withdrawal of therapy in patients with lupus nephritis

8 HIV and diarrhea in the era of HAART: 1998 New York State hospitalizations

9 Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori

10 Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis

11 Telaprevir for previously untreated chronic hepatitis C virus infection

12 First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens

13 Comparative activities of cefuroxime, amoxicillin-clavulanic acid, ciprofloxacin, enoxacin, and ofloxacin against aerobic and anaerobic bacteria isolated from bite wounds

14 Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer

15 Single- versus multiple-dose antimicrobial prophylaxis for major surgery: a systematic review

16 Hepatic candidiasis: an increasing problem in immunocompromised patients

17 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America

18 Rapid resolution of cellulitis in patients managed with combination antibiotic and anti-inflammatory therapy

19 Comparison of single and combination antimicrobial agents for prevention of experimental gas gangrene caused by Clostridium perfringens

20 Longitudinal follow-up of patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis

21 Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial

22 Vedolizumab as induction and maintenance therapy for ulcerative colitis

23 A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies

24 Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group

25 Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus

26 Community-acquired bacterial meningitis in adults

27 Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study

28 A comparative double blind study of amoxycillin/clavulanate vs placebo in the prevention of infection after animal bites

29 Boceprevir for untreated chronic HCV genotype 1 infection

30 Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa

31 Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

32 A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia

33 Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone

34 Zidovudine therapy protects against Salmonella bacteremia recurrence in human immunodeficiency virus-infected patients

35 Hemophagocytic lymphohistiocytosis syndrome in Dengue hemorrhagic fever

36 Relapse of erysipelas following treatment with prednisolone or placebo in addition to antibiotics: a 1-year follow-up

37 Science and pragmatism in the treatment and prevention of neutropenic infection

38 Application of the IDSA guidelines for the use of antimicrobial agents in neutropenic patients: impact on reducing the use of glycopeptides

39 Effect of combination antiretroviral therapy upon rectal mucosal HIV RNA burden and mononuclear cell apoptosis

40 Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients

41 Use of corticosteroids in treating infectious diseases

42 Antibiotic and prednisolone therapy of erysipelas: a randomized, double blind, placebo-controlled study

43 Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients

44 Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial

45 Secondary hemophagocytic lymphohistiocytosis in children: an analysis of etiology and outcome

46 Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens

47 High-dosage co-amoxiclav in a single dose versus 7 days of co-trimoxazole as treatment of uncomplicated lower urinary tract infection in women

48 Regulation by granulocyte-macrophage colony-stimulating factor and/or steroids given in vivo of proinflammatory cytokine and chemokine production by bronchoalveolar macrophages in response to Aspergillus conidia

49 Emergence of multidrug-resistant Salmonella typhi in rural southern India

50 Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis

51 Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

52 Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial

53 A case-control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria

54 Effects of postmeal exercise on postprandial glucose excursions in people with type 2 diabetes treated with add-on hypoglycemic agents

55 Nosocomial transmission of Saccharomyces cerevisiae in bone marrow transplant patients

56 Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study

57 Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions

58 An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens

59 Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis

60 Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients

61 Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

62 Recurrent neonatal sepsis and progressive white matter injury in a premature newborn culture-positive for group B Streptococcus: A case report

63 [Treatment of immune thrombocytopenia: a retrospective study of 40 patients]

64 Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies

65 Gentamicin and tetracyclines for the treatment of human plague: review of 75 cases in new Mexico, 1985-1999

66 Chronic hepatitis B

67 The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

68 Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

69 Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses

70 Sofosbuvir for previously untreated chronic hepatitis C infection

71 Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada

72 Lymphatic filariasis and onchocerciasis

73 Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice

74 A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin

75 De-stiffening drug therapy and blood pressure control

76 De-stiffening drug therapy and blood pressure control

77 Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy.

78 Nonclinical evaluation of IQG-607, an anti-tuberculosis candidate with potential use in combination drug therapy

79 Serum glutamine synthetase activity as biomarker for tuberculosis diagnosis and monitoring anti-tubercular drug therapy success

80 Analysis of Fractional-Order Deterministic HIV/AIDS Model During Drug Therapy Treatment

81 Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.

82 Antimicrobial Drug Therapy Problems Among Patients in the Outpatient Department of Ataye Hospital, Northeast Ethiopia

83 collaborative drug therapy agreement topics in the state of washington: from dispensing pills to managing ills

84 kinetics of central macular thickness reduction in patients with macular edema after intravitreal drug therapy

85 treating children with bronchial asthma that is resistant to traditional drug therapy

86 changes of nitric oxide and peroxynitrite serum levels during drug therapy in patients with obsessive-compulsive disorder

87 não-adesão à terapêutica medicamentosa do glaucoma noncompliance with drug therapy for glaucoma

88 performance of cpred/cobs concentration ratios as a metric reflecting adherence to antidepressant drug therapy

89 Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy

Keyword Connections

Journals

Research Groups

Bibliographies